Document is current

Article History

Received: 9 August 2022

Accepted: 11 January 2023

First Online: 21 February 2023

Declarations

:

: All mouse work conducted in the frame work of this project was performed according to the European Communities Council Directive (86/609/EEC) and was approved by the committee responsible for animal ethics of the government of Upper Bavaria (02–19-067) and in accordance to the criteria outlined by the German governments (Ministerium für Energiewende, Landwirtschaft, Umwelt und ländliche Räume Schleswig-Holstein). BACE1−/− and control mice were breed in the pathogen-free animal facilities of the Center for Stroke and Dementia Research (CSD) in Munich or the animal facility of Kiel University (Victor-Hensen-Haus).All animal procedures of experiments with NHP were done in accordance with guidelines from the Institutional Animal Care and Use Committee at Merck.The human clinical study was conducted in accordance with International Conference on Harmonisation Good Clinical Practice guidelines and was approved by the relevant institutional review boards. Written informed consent was provided by the patients or their legal representatives. The full details of the study and study protocol were previously published [].

: RC, BS, AC and MEK are employees of Merck. SR-J has acted as a consultant and speaker for Abb-Vie, Chugai, Genentech Roche, Roche, Pfizer, and Sanofi. He also declares that he is an inventor on patents owned by CONARIS Research Institute, which develops the sgp130Fc protein Olamkicept together with the companies Ferring Pharmaceuticals and I-Mab. SR-J has stock ownership in CONARIS. All other authors declare no competing interests.